Publications by authors named "A Lage"
Brucella abortus S19 and RB51 are the most used vaccines to control bovine brucellosis worldwide; therefore, this study aimed to perform a systematic review on the effectiveness of these two vaccine strains in field studies. The literature review was conducted on April 3rd 2020 on six databases (CABI, Cochrane, PubMed, Scielo, Scopus and Web of Science) and included papers published between 1976 and 2016. The search strategy recovered a total of 5846 papers on databases and 6 papers were included due to specialists' suggestions.
View Article and Find Full Text PDFBackground: Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin-angiotensin-aldosterone cascade, and mineralocorticoid receptor antagonists may be more effective in patients with heart failure (HF) and obesity.
Objectives: This study sought to examine the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone compared with placebo, according to body mass index (BMI) in FINEARTS-HF (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure).
Methods: A total of 6,001 patients with HF with NYHA functional class II, III, and IV, a left ventricular ejection fraction of ≥40%, evidence of structural heart disease, and elevated natriuretic peptide levels were randomized to finerenone or placebo.
Article Synopsis
- Vibrio spp. are diverse bacteria with promising applications in biotechnology, particularly in antibiotic resistance and the production of useful compounds.
- The study isolated 18 Vibrio strains from two different marine environments, including polluted urban settings and isolated volcanic regions, to explore their industrial applications.
- Results showed multiple strains had antimicrobial properties and could produce bioemulsifiers, alongside genetic insights into their enzymatic capabilities, underscoring their potential as valuable sources for high-value bioproducts.
Article Synopsis
- * The FINEARTS-HF trial compared the effectiveness of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, against a placebo, measuring primary outcomes like cardiovascular death and HF worsening events.
- * Results showed that lower KCCQ Total Symptom Scores (TSS) indicated a higher risk of adverse events, but finerenone significantly reduced event risks across all KCCQ TSS tertiles, suggesting it may improve outcomes for patients with varying levels of symptom severity.
Article Synopsis
- Finerenone demonstrates positive outcomes for patients with heart failure and varying degrees of ejection fraction, specifically HFmrHF and HFpEF, in a large clinical trial involving 6,001 participants aged 40-97.
- The analysis revealed that while the incidence of adverse cardiovascular outcomes increased with age, finerenone consistently reduced the risk of these outcomes across all age groups.
- Safety profiles, including the occurrence of hypotension and changes in potassium levels, showed no significant differences among age categories, suggesting that finerenone is safe and effective regardless of age.